Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro

Journal of Cellular Physiology

Volumn 228, Issue 6, 2013, Pages 1344-1350

  Carr, Brian I ^a   D'Alessandro, Rosalba ^a   Refolo, Maria G ^a   Iacovazzi, Palma A ^a   Lippolis, Catia ^a   Messa, Caterina ^a   Cavallini, Aldo ^a   Correale, Mario ^a   Di Carlo, Antonio ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; REGORAFENIB; SORAFENIB;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84874213826     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24291     Document Type: Article

References (17)

1. Adnane L, Trail PA, Taylor I, Wilhelm SM. 2006. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612.
2. Carr BI, Pancoska P, Branch RA. 2009. Tumor and liver determinants of prognosis in unresecable hepatocellular carcinoma: A large case cohort study. Hepatol Int 4:396-405.
3. Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Tafaro A. 2013. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence and recovery. J Cell Physiol 228:272-297.
4. Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C. 2011. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and Sorafenib. Br J Cancer 105:1811-1813.
5. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M, SOFIA (SoraFenibItalianAssessment) study group. 2011. Field-practice study of Sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 54:2055-2063.
6. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. 2012. Sorafenib dose escalation in the treatment of advance hepatocellular carcinoma. Oncology 82:119-125.
7. Liang CC, Park AY, Guan JL. 2007. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333.
8. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Group Study. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
10. Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB III, Mulcahy MF, Omary RA, Salem R. 2012. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J Hepatol 56:1112-1120.
11. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. 2012. Usefulness of alpha-fetoprotein response in patients treated with Sorafenib for advanced hepatocellular carcinoma. J Hepatol 57:101-107.
12. Rose A, Grandoch M, vomDorp F, Rubben H, Rosenkranz A, Fischer JW, Weber AA. 2010. Stimulatory effects of the multi-kinase inhibitor Sorafenib on human bladder cancer cells. Br J Pharmacol 160:1690-1698.
13. Schutz FA, Je Y, Choueiri TK. 2011. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase Sorafenib: A meta-analysis of clinical trials. Crit Rev Oncol Hematol 80:291-300.
14. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. 2010. Vitamin K enhancement of Sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 127:2949-2958.
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnone L, Lynch M, Auclair D, taylor I, Gendrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
16. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. 2011. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255.
17. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. 2011. Meta-analysis of dermatological toxicities associated with Sorafenib. Clin Exp Dermatol 36:344-350.